Plasma NGAL and glomerular filtration rate in cardiac transplant recipients treated with standard or reduced calcineurin inhibitor levels

Biomark Med. 2014;8(2):239-45. doi: 10.2217/bmm.13.95.

Abstract

Aim: Predictors of renal recovery following conversion from calcineurin inhibitor- to proliferation signal inhibitor-based therapy are lacking. We hypothesized that plasma NGAL (P-NGAL) could predict improvement in glomerular filtration rate (GFR) after conversion to everolimus.

Patients & methods: P-NGAL was measured in 88 cardiac transplantation patients (median 5 years post-transplant) with renal dysfunction randomized to continuation of conventional calcineurin inhibitor-based immunosuppression or switching to an everolimus-based regimen.

Results: P-NGAL correlated with measured GFR (mGFR) at baseline (R(2) = 0.21; p < 0.001). Randomization to everolimus improved mGFR after 1 year (median [25-75 % percentiles]: ΔmGFR 5.5 [-0.5-11.5] vs -1 [-7-4] ml/min/1.73 m(2); p = 0.006). Baseline P-NGAL predicted mGFR after 1 year (R(2) = 0.18; p < 0.001), but this association disappeared after controlling for baseline mGFR.

Conclusion: P-NGAL and GFR correlate with renal dysfunction in long-term heart transplantation recipients. P-NGAL did not predict improvement of renal function after conversion to everolimus-based immunosuppression.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acute-Phase Proteins
  • Aged
  • Calcineurin / metabolism
  • Calcineurin Inhibitors*
  • Creatinine / blood
  • Everolimus
  • Female
  • Follow-Up Studies
  • Glomerular Filtration Rate
  • Graft Rejection / drug therapy*
  • Graft Rejection / prevention & control
  • Heart Failure / surgery*
  • Heart Transplantation*
  • Humans
  • Immunosuppressive Agents / therapeutic use*
  • Lipocalin-2
  • Lipocalins / blood*
  • Male
  • Middle Aged
  • Proto-Oncogene Proteins / blood*
  • Sirolimus / analogs & derivatives
  • Sirolimus / therapeutic use

Substances

  • Acute-Phase Proteins
  • Calcineurin Inhibitors
  • Immunosuppressive Agents
  • LCN2 protein, human
  • Lipocalin-2
  • Lipocalins
  • Proto-Oncogene Proteins
  • Everolimus
  • Creatinine
  • Calcineurin
  • Sirolimus